One potential earnings short-squeeze play in the biotechnology and drugs complex is Hi-Tech Pharmacal (HITK), which is set to release numbers on Wednesday before the market open. This company is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. Wall Street analysts, on average, expect Hi-Tech Pharmacal to report revenue of $57.56 million on earnings of 68 cents per share.
The current short interest as a percentage of the float for Hi-Tech Pharmacal is sits at 4.9%. That means that out of the 10.58 million shares in the tradable float, 509,000 shares are sold short by the bears. This isn't a huge short interest, but it's more than enough to spark a decent short-covering rally post-earnings if the bulls get the news they're looking for.From a technical perspective, HITK is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has been on a tear during the last two months, with shares soaring from a low of $27.35 to a recent high of $36.27 a share. During that sharp spike higher, shares of HITK have consistently made higher lows and higher highs, which is bullish technical price action. That move has now pushed HITK within range of triggering a near-term breakout trade post-earnings. If you're bullish on HITK, then I would wait until after they report and look for long-biased trades if this stock can manage to take out some near-term overhead resistance levels at $36.27 to $36.49 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 92,196 shares. If we get that move, then HITK will setup to re-test and possibly take out its next overhead resistance level at $38.16 a share. If $38.16 gets taken out with volume, then HITK could trend back towards $40 to $43 a share post-earnings. I would avoid HITK or look for short-biased trades if after earnings it fails to trigger that breakout, and then drops below some near-term support at $34.53 a share with heavy volume. If we get that action, then HITK could easily take out its 50-day moving average of $33.21 a share, and then drop lower towards $30 to $29 a share post-earnings.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV